Urgent

Antisynthetase syndrome

Myositis with interstitial lung disease · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

An inflammatory myopathy associated with anti-tRNA-synthetase antibodies (commonly anti-Jo-1) presenting with the triad of myositis, interstitial lung disease and arthritis, often with mechanic's hands, Raynaud phenomenon and fever. Interstitial lung disease drives morbidity and may be the dominant or presenting feature.

Red flags

  • Rapidly progressive dyspnoea / hypoxaemia
  • Dysphagia and aspiration risk
  • Respiratory muscle weakness with falling vital capacity
  • Fever with worsening infiltrates
  • New cardiac symptoms (myocarditis)

Assessment

Differential diagnosis

  • Idiopathic inflammatory myopathy (DM/PM)
  • Other connective-tissue-disease ILD
  • Rheumatoid arthritis with ILD
  • Idiopathic pulmonary fibrosis
  • Statin/immune-mediated necrotising myopathy
  • Hypothyroid myopathy

Investigations

  • Creatine kinase, LDH, aldolase (raised)
  • Myositis-specific antibody panel (anti-Jo-1, PL-7, PL-12, EJ, OJ)
  • High-resolution CT chest (NSIP/organising pneumonia pattern) and lung function with transfer factor
  • EMG and MRI thigh / muscle biopsy
  • ANA, anti-Ro52 (associated with severe ILD)
  • Malignancy screen as clinically indicated

Management

  • Assess respiratory status and muscle strength including bulbar/respiratory muscles
  • Confirm with myositis antibody panel, CK and HRCT chest
  • Screen for aspiration risk (pharyngeal weakness) and oxygenation
  • Start corticosteroids as first-line for both myositis and ILD
  • Add a steroid-sparing immunosuppressant early, especially with significant ILD
  • Treat rapidly progressive ILD aggressively with combination immunosuppression
  • Arrange swallow assessment, physiotherapy and pulmonary rehabilitation
  • Monitor lung function and CK; coordinate long-term care with rheumatology and respiratory

Drugs & doses

Prednisolone — 0.5-1 mg/kg/day PO (up to 60 mg) with slow taper
Methylprednisolone — 500 mg-1 g IV OD x3 for severe myositis/ILD
Mycophenolate mofetil — 1 g PO BD (up to 1.5 g BD)
Tacrolimus — 0.075 mg/kg/day PO in divided doses, adjusted to trough levels
Rituximab — 1 g IV days 1 and 15 for refractory disease

Disposition

Admit if significant ILD, aspiration risk or respiratory compromise; otherwise urgent joint rheumatology-respiratory clinic.

Complications & pitfalls

  • Progressive interstitial lung disease / respiratory failure
  • Aspiration pneumonia
  • Myocarditis
  • Associated malignancy
  • Immunosuppression-related infection

Exam pearls

  • ILD may precede or dominate over muscle disease; CK can be normal in amyopathic presentations
  • Anti-Jo-1 is the commonest antibody; anti-PL-7/PL-12 associate with more severe ILD and less myositis
  • Mechanic's hands and Raynaud are useful clinical clues
  • Anti-Ro52 co-positivity predicts worse lung disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.